To evaluate growth inhibitory efficacy of CDK4/6 and JAK1/2 inhibition separately, the NKTCL cell lines were treated to a range of LEE011 and ruxolitinib concentrations. The gene discussed is JAK1; the disease is extranodal nasal NK/T cell lymphoma.